Vascular Biogenics Ltd. (NASDAQ:VBLT) shares, rose in value on Thursday, 08/04/22, with the stock price up by 1.25% to the previous day’s close as strong demand from buyers drove the stock to $0.24.
Actively observing the price movement in the last trading, the stock closed the session at $0.24, falling within a range of $0.236 and $0.2575. The value of beta (5-year monthly) was 1.09. Referring to stock’s 52-week performance, its high was $2.54, and the low was $0.21. On the whole, VBLT has fluctuated by -86.50% over the past month.
With the market capitalization of Vascular Biogenics Ltd. currently standing at about $19.22 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 23, 2022 – Mar 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.11, which is expected to increase to -$0.11 for fiscal year -$0.49 and then to about -$0.45 by fiscal year 2023. Data indicates that the EPS growth is expected to be -8.90% in 2023, while the next year’s EPS growth is forecast to be 8.20%.
Analysts have estimated the company’s revenue for the quarter at $1.16 million, with a low estimate of $100k and a high estimate of $2.7 million. According to the average forecast, sales growth in current quarter could jump up 517.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $2.16 million, representing an increase of 181.30% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VBLT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VBLT currently trading nearly -77.06% and -82.18% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 23.04, while the 7-day volatility ratio is showing 12.80% which for the 30-day chart, stands at 13.29%. Furthermore, Vascular Biogenics Ltd. (VBLT)’s beta value is 0.67, and its average true range (ATR) is 0.13.
A comparison of Vascular Biogenics Ltd. (VBLT) with its peers suggests the former has fared considerably weaker in the market. VBLT showed an intraday change of 1.25% in last session, and over the past year, it shrunk by -88.70%%. In comparison, Merrimack Pharmaceuticals Inc. (MACK) has moved higher at 0.94% on the day and was down -17.47% over the past 12 months. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.08%. Meanwhile, the Dow Jones Industrial Slipped by -0.26%.
Data on historical trading for Vascular Biogenics Ltd. (NASDAQ:VBLT) indicates that the trading volumes over the past 10 days have averaged 10.57 million and over the past 3 months, they’ve averaged 2.29 million. According to company’s latest data on outstanding shares, there are 77.39 million shares outstanding.
Nearly 23.95% of Vascular Biogenics Ltd.’s shares belong to company insiders and institutional investors own 20.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.29 million shares as on Jul 14, 2022, resulting in a short ratio of 1.92. According to the data, the short interest in Vascular Biogenics Ltd. (VBLT) stood at 0.42% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 0.33 million. The stock has fallen by -87.66% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VBLT stock heading into the next quarter.